ARTV · Artiva Biotherapeutics

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.

5505 Morehouse Drive, San Diego, CA, 92121, United States
Biotechnology
Healthcare

Market Cap

186.9M

52 Wk Range

$2.96 - $14.53

Previous Close

$3.83

Open

$3.82

Volume

1,775,381

Day Range

$3.77 - $3.93

Enterprise Value

-120.6M

Cash

319.1M

Avg Qtr Burn

-28.45M

Insider Ownership

14.43%

Institutional Own.

83.61%

Qtr Updated

Sep 30th 2026